OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46
Showing 26-50 of 46 citing articles:
Unveiling renoprotection: A comprehensive review of SGLT2 inhibitors, with emphasis on empagliflozin in the treatment of chronic kidney disease
Swathi Madagam
Urinary and Renal Research (2024) Vol. 5, Iss. 1
Open Access
Swathi Madagam
Urinary and Renal Research (2024) Vol. 5, Iss. 1
Open Access
Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia
Siwei Deng, Houyu Zhao, Sanbao Chai, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
Siwei Deng, Houyu Zhao, Sanbao Chai, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease
Xiaohong Chen, Chang Xu, Ke Hu, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 10, pp. 991-998
Closed Access | Times Cited: 1
Xiaohong Chen, Chang Xu, Ke Hu, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 10, pp. 991-998
Closed Access | Times Cited: 1
Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100179-100179
Open Access | Times Cited: 1
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100179-100179
Open Access | Times Cited: 1
Canagliflozin ameliorates neuronal injury after cerebral ischemia reperfusion by targeting SGLT1 and AMPK-dependent apoptosis
Zhaoxu Zheng, Xiheng Chen, Yisen Zhang, et al.
Neurotherapeutics (2023) Vol. 21, Iss. 2, pp. e00305-e00305
Open Access | Times Cited: 1
Zhaoxu Zheng, Xiheng Chen, Yisen Zhang, et al.
Neurotherapeutics (2023) Vol. 21, Iss. 2, pp. e00305-e00305
Open Access | Times Cited: 1
Comment on "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies"
Mei Qiu, Wei Xu-bin, Wei Wei
Pharmacological Research (2021) Vol. 172, pp. 105862-105862
Closed Access | Times Cited: 2
Mei Qiu, Wei Xu-bin, Wei Wei
Pharmacological Research (2021) Vol. 172, pp. 105862-105862
Closed Access | Times Cited: 2
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care
Dongdong Wang, Cun Zhang, Yang Yang, et al.
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-8
Open Access | Times Cited: 1
Dongdong Wang, Cun Zhang, Yang Yang, et al.
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-8
Open Access | Times Cited: 1
Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
Annalisa Capuano, Emilio Clementi, Giuseppe Paolisso
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 1
Annalisa Capuano, Emilio Clementi, Giuseppe Paolisso
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 1
Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?
Limin Zhao, Huang Jian-an, Mei Qiu, et al.
Pharmacological Research (2021) Vol. 174, pp. 105878-105878
Closed Access | Times Cited: 1
Limin Zhao, Huang Jian-an, Mei Qiu, et al.
Pharmacological Research (2021) Vol. 174, pp. 105878-105878
Closed Access | Times Cited: 1
Crosstalk Between Abnormal Electrical Activity and Angiotensin II Cell Signaling in the Hyperglycemic Mammalian Heart
Belma Turan
Advances in biochemistry in health and disease (2023), pp. 39-62
Closed Access
Belma Turan
Advances in biochemistry in health and disease (2023), pp. 39-62
Closed Access
Are Sodium-Glucose Cotransporter–2 (SGLT2) Inhibitors related to falls in cardiometabolic patients? An European Pharmacovigilance Analysis
Annamaria Mascolo, Concetta Rafaniello, Donatella Ruggiero, et al.
Research Square (Research Square) (2023)
Open Access
Annamaria Mascolo, Concetta Rafaniello, Donatella Ruggiero, et al.
Research Square (Research Square) (2023)
Open Access
Effects of Antidiabetic Medications on Cardiovascular Outcomes in Patients With Heart Failure
Tomoyuki Kawada
The American Journal of Cardiology (2022) Vol. 167, pp. 165-165
Open Access
Tomoyuki Kawada
The American Journal of Cardiology (2022) Vol. 167, pp. 165-165
Open Access
SGLT-2i para a prevenção de eventos cardiovasculares em portadores com Diabetes mellitus tipo 2
Wellington Felipe do Nascimento Barros, Fábio Henrique Portella Corrêa de Oliveira
Research Society and Development (2022) Vol. 11, Iss. 8, pp. e18211830528-e18211830528
Open Access
Wellington Felipe do Nascimento Barros, Fábio Henrique Portella Corrêa de Oliveira
Research Society and Development (2022) Vol. 11, Iss. 8, pp. e18211830528-e18211830528
Open Access
Cardiovascular and Renal Outcomes among Patients with Type 2 Diabetes using SGLT2 Inhibitors added to Metformin: A Population-Based Cohort Study from the United Kingdom
Antonio González‐Pérez, David Vizcaya, María Eugenia Sáez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Antonio González‐Pérez, David Vizcaya, María Eugenia Sáez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Sodium-Glucose Cotransporter-2 (SGLT2) Expression in Diabetic and Non-Diabetic Failing Human Cardiomyocytes
Raffale Marfella, Lucia Scisciola, Nunzia D’ Onofrio, et al.
SSRN Electronic Journal (2022)
Closed Access
Raffale Marfella, Lucia Scisciola, Nunzia D’ Onofrio, et al.
SSRN Electronic Journal (2022)
Closed Access
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’
Ameenathul M. Fawzy, José Miguel Rivera‐Caravaca, Laurent Fauchier, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 630-633
Closed Access
Ameenathul M. Fawzy, José Miguel Rivera‐Caravaca, Laurent Fauchier, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 630-633
Closed Access
Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
Dongdong Wang, Cun Zhang, Ping Zhu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access
Dongdong Wang, Cun Zhang, Ping Zhu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access
Targeting High Glucose-Induced Epigenetic Modifications at Cardiac Levels: The Role of SGLT2 and SGLT2 Inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Research Square (Research Square) (2022)
Open Access
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Research Square (Research Square) (2022)
Open Access
Response to the comment on "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies"
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105863-105863
Closed Access
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105863-105863
Closed Access
Cardiorenal benefits of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in type 2 diabetes without cardiovascular and renal diseases
Mei Qiu, Xian Liang Zhou, Miao Zhang
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 575-577
Closed Access
Mei Qiu, Xian Liang Zhou, Miao Zhang
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 575-577
Closed Access
Response to the comment “Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?”
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 174, pp. 105876-105876
Closed Access
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 174, pp. 105876-105876
Closed Access
